Sanjivani Parenteral Reports 8.9% Revenue Growth in Q1, Pune Facility Set for Commercial Production
Sanjivani Parenteral Limited, a WHO-GMP certified pharmaceutical company, reported Q1 revenue growth of 8.9% YoY to INR 17.90 crores. EBITDA increased by 10.8% to INR 2.70 crores, with margins improving to 15.00%. The company maintains a 73.70%-26.30% export-domestic revenue mix, exporting to over 25 countries. Their new Pune facility is expected to begin commercial production by early September. The company added 8 new products in Q1 and Q2 combined and is focusing on expanding in LATAM and French-speaking African markets. Despite logistical challenges, management remains optimistic, providing a full-year revenue guidance of INR 75-80 crores.
12Aug 25
Sanjivani Paranteral Reports 8.9% Revenue Growth in Q1 FY26, Driven by Strong Injectables Performance
Sanjivani Paranteral Limited reported an 8.9% year-over-year revenue growth to ₹178.90 crore for Q1 FY26. EBITDA increased by 10.8% to ₹26.80 crore, while PAT grew marginally by 1.0% to ₹17.30 crore. The injectables segment showed robust growth of 47.1%, but the oral segment declined by 11.1% due to shipment challenges. Exports constituted 73.7% of total revenue, with core markets in CIS, Middle East & Africa, and Latin America contributing significantly. The company remains focused on R&D and expanding its product portfolio to drive future growth.